Red dye 3 ban — global regulatory landscape and tablet coatings alternatives
Regulatory authorities worldwide are moving to ban Red Dye 3 (erythrosine) in oral medications, with the US FDA’s ban effective January 2028 as a clear industry deadline. This shift is part of broader safety trends that also affect food and dietary supplements, driven by historical toxicology concerns and coordinated actions in regions like Latin America and Europe. For pharmaceutical manufacturers, the phase-out represents both a regulatory challenge and a strategic opportunity. Early reformulation efforts can prevent supply chain disruptions, manufacturing delays, and competitive disadvantages. The article highlights the importance of science-backed coating alternatives—both synthetic and natural—that meet compliance requirements while maintaining film coating performance. Proactive regulatory intelligence and technical innovation in coatings can help manufacturers align products with evolving global standards and consumer expectations.
Comments
No comments posted yet.
Articles you may like
Related products
Looking for additional information?
Let us help you